Ulta Lab Tests

Cardiac Risk Panel

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: ApoE Genotype, ApoE Genotype Cardio IQ, Apolipoprotein E Genotype, Cardio IQ ApoE Genotype

Apoe Genotype

The test for ApoE is may be used in combination with other lipid tests that evaluate risk for CVD, such as cholesterol levels and lipoprotein electrophoresis. It may be used to check for and help to diagnose a genetic component to a lipid abnormality. Testing for ApoE may sometimes be ordered to help guide lipid treatment. In cases of high cholesterol and triglyceride levels, statins are usually considered the treatment of choice to decrease the risk of developing CVD. However, there is a wide variability in the response to these lipid-lowering drugs that is in part influenced by the Apo E genotype. Though appropriately responsive to a low fat diet, people with ApoE e4 may be less likely than those with ApoE e2 to respond to statins by decreasing their levels of LDL-C and may require adjustments to their treatment plans In Alzheimer's Disease - ApoE genotyping is also sometimes used as an adjunct test to help in the diagnosis of probable late onset Alzheimer's disease (AD) in symptomatic adults. It is called susceptibility or risk factor testing because it indicates whether there is an increased risk of AD but is not specifically diagnostic of AD. If a patient has dementia, the presence of ApoE4 may increase the likelihood that the dementia is due to AD, but does not prove that it is.

Guidance Statements

Method

Reviewer

LP PLA2 ACTIVITY

Also known as: Lipoprotein A, Lp (a), Lp(a)

Lipoprotein (A)

Lipoprotein-a, or Lp(a) are molecules made of proteins and fat. They carry cholesterol and similar substances through the blood. A high level of Lp(a) is considered a risk factor for heart disease. High levels of lipoproteins can increase the risk of heart disease. The test is done to check your risk of atherosclerosis, stroke, and heart attack.

Also known as: Methylenetetrahydrofolate Reductase MTHFR DNA Mutation Analysis, MTHFR

Methylenetetrahydrofolate

RESULT

Also known as: Anti-Myeloperoxidase, Churg-Strauss Syndrome, Crescentic Glomeruloephritis, MPO, Myeloperoxidase Antibody MPO

Myeloperoxidase Antibody

Antineutrophil cytoplasmic antibodies (ANCA) are a group of autoantibodies produced when a person's immune system mistakenly targets and attacks its own neutrophil proteins. Two of the most commonly targeted proteins are myeloperoxidase (MPO) and proteinase 3 (PR3). This results in the production of antibodies to MPO and/or PR3. The ANCA blood test detects the presence or absence of these autoantibodies. Antineutrophil cytoplasmic antibodies may be present in a variety of autoimmune disorders that cause inflammation and damage to blood vessels throughout the body (systemic vasculitis). Vasculitis can cause tissue and organ damage due to the narrowing and obstruction of blood vessels and the subsequent loss of blood supply. It can also produce areas of weakness in blood vessel walls, known as aneurysms, which have the potential to rupture.

ARACHIDONIC ACID

ARACHIDONIC ACID/EPA

DHA

DPA

EPA

EPA+DPA+DHA

LINOLEIC ACID

OMEGA-3 TOTAL

OMEGA-6 TOTAL

OMEGA-6/OMEGA-3 RATIO

Also known as: BNP, N-terminal pro b-type natriuretic peptide, proBNP Nterminal

Probnp, N Terminal

N-terminal pro b-type natriuretic peptide (NT-proBNP) used to detect and evaluate heart failure. BNP is actually produced primarily by the left ventricle of the heart (the heart's main pumping chamber). It is associated with blood volume and pressure and with the work that the heart must do in pumping blood throughout the body.When the left ventricle of the heart is stretched, the concentrations of NT-proBNP produced can increase markedly. This situation indicates that the heart is working harder and having more trouble meeting the body's demands. This may occur with heart failure as well as with other diseases that affect the heart and circulatory system. It does not mean that the heart has stopped working; it just means that it is not pumping blood as effectively as it should be. NT-proBNP concentrations will reflect this diminished capacity.
*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through a national lab. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.

The Cardiac Risk Panel panel contains 7 tests with 20 biomarkers .

The Cardiac Risk Panel:

The Cardiac Risk Panel provides a comprehensive assessment designed to provide you with valuable insights into your cardiovascular health and potential risks.

By analyzing a range of markers, including genetic factors, inflammation indicators, lipid metabolism, and cardiac stress markers, this panel offers a personalized approach to understanding your unique cardiac risk profile.

With the information provided by the Cardiac Risk Panel, you can take proactive steps to manage your cardiovascular health, make informed lifestyle choices, and work closely with healthcare professionals to reduce your risk of cardiovascular disease.

  • CARDIO IQ™ LP PLA2 Activity: LP PLA2 (Lipoprotein-associated phospholipase A2) is an enzyme involved in the inflammatory process within blood vessels. Measuring LP PLA2 activity through the CARDIO IQ™ test can help assess the risk of plaque buildup and inflammation in the arteries, which are significant contributors to cardiovascular disease.
  • Lipoprotein (A): Lipoprotein (a) is a type of lipoprotein-associated with an increased risk of cardiovascular disease. Measuring the level of lipoprotein (a) in the blood can provide insights into your potential risk for developing heart-related conditions.
  • Methylenetetrahydrofolate Reductase (MTHFR), DNA Mutation Analysis: The MTHFR gene encodes an enzyme involved in folate metabolism. DNA mutation analysis of the MTHFR gene can identify specific variants, such as C677T and A1298C, which may impact the efficiency of the MTHFR enzyme. These variants have been associated with altered folate metabolism and potential health implications.
  • Myeloperoxidase Antibody (MPO): Myeloperoxidase is an enzyme produced by white blood cells that plays a role in the development and progression of atherosclerosis. Measuring the levels of myeloperoxidase antibodies can help assess inflammation and oxidative stress in the arteries, providing insights into cardiovascular risk.
  • Omega-3 and -6 Fatty Acids, Plasma: Omega-3 and -6 fatty acids are essential fats that play a crucial role in cardiovascular health. Measuring the levels of these fatty acids in plasma can provide insights into your dietary intake and balance of these beneficial fats, which can influence cardiovascular risk factors.
  • proBNP, N-terminal: ProBNP (N-terminal pro-brain natriuretic peptide) is a marker used to assess heart function and detect the presence of heart failure. Measuring proBNP levels can help evaluate cardiac stress and identify potential cardiac abnormalities.

The Cardiac Risk Panel offers a comprehensive evaluation of your cardiovascular health, providing you with valuable information about your genetic predispositions, inflammation markers, lipid metabolism, and cardiac stress indicators.

By understanding your unique cardiac risk profile, you can take proactive measures to mitigate potential risks and optimize your cardiovascular well-being.

Armed with this knowledge, you can make informed decisions about lifestyle modifications, collaborate closely with healthcare professionals, and embrace a proactive approach to heart health. Remember, early detection, personalized interventions, and ongoing management are key to maintaining a healthy heart and reducing the likelihood of cardiovascular disease. Take charge of your cardiovascular health today with the insights provided by the Cardiac Risk Panel.

Customer Reviews